APPLICATION
ANDA076565
TYPE
ANDA
ORIGINAL APPROVAL
2010-06-28
LATEST ACTION
2024-08-12
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
2024-08-12Labeling · Supplement 23 · standardAP
2023-03-24Labeling · Supplement 21 · standardAP
2023-03-24Labeling · Supplement 22 · standardAP
2020-11-03Labeling · Supplement 17 · standardAP
2020-11-03Labeling · Supplement 15 · standardAP
2020-11-03Labeling · Supplement 13 · standardAP
2020-11-03Labeling · Supplement 16 · standardAP
2020-11-03Labeling · Supplement 14 · standardAP
2015-10-01Labeling · Supplement 11 · standardAP
2014-09-19Labeling · Supplement 10 · standardAP
2014-09-19Labeling · Supplement 6 · standardAP
2014-09-19Labeling · Supplement 4 · standardAP
2014-09-19Labeling · Supplement 5 · standardAP
2012-09-19Labeling · Supplement 3 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.